[Home ] [Archive]   [ فارسی ]  
:: Volume 3, Issue 4 (COVID-19 Supplement 2021) ::
J Mar Med 2021, 3(4): 89-95 Back to browse issues page
Design and efficacy of L-CapA-L-CapC Anticancer-L-RIb-Streptococcus agalactiae fusion protein against COVID-19
Elmira Babakanrad, Taher Mohamadian * , Davoud Esmaeili , Payam Behzadi
Department of Microbiology, Shahr-e-Qods Branch, Islamic Azad University, Tehran, Iran , tmohammadian@qodsiau.ac.ir
Abstract:   (183 Views)
Background and Aim: SARS-CoV-2 was identified in late 2019 as a respiratory disease agent called COVID-19. Several drug therapies have been studied to treat COVID-19, none of which have had a definite effect so far. In mild cases of the disease, treatment is careful to reduce the symptoms of the disease, and in severe cases, the patient must be hospitalized to receive different treatments. There are several medications available, many of which are still being evaluated, and there is still no definitive cure for COVID-19
Methods: In this study, an attempt is made to investigate various treatment methods, including the use of L-CapA-L-CapC Anticancer-L-Rib-fusion protein in the treatment of COVID-19 in terms of bioinformatics. In this study, the use of bacterial peptides antiviral drugs is emphasized to introduce appropriate treatment to control SARS-CoV-2
Results: L-CapA-L-CapC Anticancer-L-Rib- fusion protein and Spike virus sequences were extracted using NCBI database. Then, using various software such as SWISS-MODEL and Expasy, the structural model of the protein and its quality were determined. The immunogenicity of L-CapA-L-CapC Anticancer-L-Rib fusion protein was also evaluated.
Conclusion: Based on the bioinformatics results, L-CapA-L-CapC Anticancer-L-Rib fusion protein has a dense and complex structure and in addition to its anti-cancer and anti-viral properties, it can be used in the treatment of COVID-19.
Keywords: Coronavirus, COVID-19, Bioinformatics, Antibiotics.
Full-Text [PDF 910 kb]   (80 Downloads)    
Type of Study: Original Article | Subject: Marine Medicine
Received: 2021/08/25 | Accepted: 2021/08/31 | Published: 2021/09/1
Send email to the article author

Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Babakanrad E, Mohamadian T, Esmaeili D, Behzadi P. Design and efficacy of L-CapA-L-CapC Anticancer-L-RIb-Streptococcus agalactiae fusion protein against COVID-19. J Mar Med. 2021; 3 (4) :89-95
URL: http://jmarmed.ir/article-1-299-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 3, Issue 4 (COVID-19 Supplement 2021) Back to browse issues page
مجله طب دریا Journal of Marine Medicine
Persian site map - English site map - Created in 0.07 seconds with 29 queries by YEKTAWEB 4353